Literature DB >> 22737268

An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.

Pamela A Smith1, David Merritt, Leah Barr, David A Thorley-Lawson.   

Abstract

To define and therapeutically target mechanisms that mediate nasopharyngeal carcinoma (NPC) metastasis, we have developed a unique orthotopic xenograft mouse model that accurately recapitulates the invasive and metastatic behavior of human disease. Based on clinical and laboratory evidence that the PI3K/Akt/mTOR axis is involved in aggressive NPC tumor behavior, we chose it as a therapeutic target to test the utility of our orthotopic system for evaluating the effectiveness of a targeted treatment for metastatic NPC. Demonstrated herein, we have shown that both the development and growth of metastatic lesions are markedly reduced by the mTOR inhibitor sirolimus. Thus, this orthotopic model provides a platform to study potential therapeutics for advanced NPC and demonstrates that targeting the PI3K/Akt/mTOR pathway is a promising intervention against disseminated disease.

Entities:  

Keywords:  mTOR; metastasis; nasopharyngeal carcinoma; orthotopic xenograft

Year:  2011        PMID: 22737268      PMCID: PMC3379566          DOI: 10.1177/1947601912440878

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  51 in total

Review 1.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

2.  The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

Authors:  Justin Lamb; Emily D Crawford; David Peck; Joshua W Modell; Irene C Blat; Matthew J Wrobel; Jim Lerner; Jean-Philippe Brunet; Aravind Subramanian; Kenneth N Ross; Michael Reich; Haley Hieronymus; Guo Wei; Scott A Armstrong; Stephen J Haggarty; Paul A Clemons; Ru Wei; Steven A Carr; Eric S Lander; Todd R Golub
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

3.  Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis.

Authors:  Dirk M Pegtel; Aravind Subramanian; Tzung-Shiahn Sheen; Ching-Hwa Tsai; Todd R Golub; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 4.  mTOR and cancer: insights into a complex relationship.

Authors:  David M Sabatini
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

Review 5.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

6.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.

Authors:  Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

7.  AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.

Authors:  Ling-Zhi Liu; Xiang-Dong Zhou; Guisheng Qian; Xianglin Shi; Jing Fang; Bing-Hua Jiang
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 8.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

9.  Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.

Authors:  Yu-Ping Mei; Jun-Min Zhou; Yi Wang; He Huang; Rong Deng; Gong-Kan Feng; Yi-Xin Zeng; Xiao-Feng Zhu
Journal:  Cell Cycle       Date:  2007-06-11       Impact factor: 4.534

Review 10.  Nasopharynx cancer: therapeutic value of chemoradiotherapy.

Authors:  Brian O'Sullivan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007       Impact factor: 7.038

View more
  10 in total

1.  The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo.

Authors:  Jin Qiu; Pamela Smith; Leah Leahy; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2015-01-15       Impact factor: 6.823

2.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

3.  Modeling nasopharyngeal carcinoma in three dimensions.

Authors:  Prabu Siva Sankar; Mohd Firdaus Che Mat; Kalaivani Muniandy; Benedict Lian Shi Xiang; Phang Su Ling; Susan Ling Ling Hoe; Alan Soo-Beng Khoo; Nethia Mohana-Kumaran
Journal:  Oncol Lett       Date:  2017-02-08       Impact factor: 2.967

4.  EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

Authors:  Wenfeng Fang; Jianwei Zhang; Shaodong Hong; Jianhua Zhan; Nan Chen; Tao Qin; Yanna Tang; Yaxiong Zhang; Shiyang Kang; Ting Zhou; Xuan Wu; Wenhua Liang; Zhihuang Hu; Yuxiang Ma; Yuanyuan Zhao; Ying Tian; Yunpeng Yang; Cong Xue; Yue Yan; Xue Hou; Peiyu Huang; Yan Huang; Hongyun Zhao; Li Zhang
Journal:  Oncotarget       Date:  2014-12-15

5.  Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.

Authors:  King Chi Chan; Lai Sheung Chan; Joseph Chok Yan Ip; Carman Lo; Timothy Tak Chun Yip; Roger Kai Cheong Ngan; Ricky Ngok Shun Wong; Kwok Wai Lo; Wai Tong Ng; Anne Wing Mui Lee; George Sai Wah Tsao; Michael Kahn; Maria Li Lung; Nai Ki Mak
Journal:  Sci Rep       Date:  2015-04-21       Impact factor: 4.379

6.  Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.

Authors:  Longmei Cai; Jinbang Li; Xiaona Zhang; Yaoyong Lu; Jianguo Wang; Xiaoming Lyu; Yuxiang Chen; Jinkun Liu; Hongbing Cai; Ying Wang; Xin Li
Journal:  Oncotarget       Date:  2015-04-10

Review 7.  Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

Authors:  Sin-Yeang Teow; Hooi-Yeen Yap; Suat-Cheng Peh
Journal:  J Pathog       Date:  2017-12-31

8.  Study on the Drug Targets and Molecular Mechanisms of Rhizoma Curcumae in the Treatment of Nasopharyngeal Carcinoma Based on Network Pharmacology.

Authors:  Sijia Zhai; Qiao Huang; Xingwei Liao; Shihua Yin
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-28       Impact factor: 2.629

9.  Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth.

Authors:  Franck Gallardo; Bernard Mariamé; Remi Gence; Anne-Francoise Tilkin-Mariamé
Journal:  Drug Des Devel Ther       Date:  2018-09-07       Impact factor: 4.162

10.  Microenvironmental topographic cues influence migration dynamics of nasopharyngeal carcinoma cells from tumour spheroids.

Authors:  Bowie P Lam; Sarah K C Cheung; Yun W Lam; Stella W Pang
Journal:  RSC Adv       Date:  2020-08-04       Impact factor: 3.361

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.